MP43-13 HIGH GAMMA-GLOBULIN LEVEL IS ASSOCIATED WITH ONCOLOGICAL OUTCOMES IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER
Naoya Niwa*, Kazuhiro Matsumoto, Hiroki Ide, Mototsugu Oya, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Antibody, also referred to immunoglobulin, production is the principal functions of B cell immunity. In patients with malignancy, autoantibodies against tumorassociated antigens are produced in the patient's sera by the patient's own immune system. Howeber, an increase or decrease in autoantibodies is beneficial to the oncological outcomes is still unknown. We investigated the clinical implication of gamma globulin levels, that composed almost entirely of immunoglobulin, on the oncological outcomes in patients with NMIBC.
METHODS: A total of 274 patients with NMIBC who underwent transurethral surgery between 2000 and 2015 were identified. One hundred forty-four patients (52.6%) had received adjuvant intravesical bacillus Calmette-Guerin. Gamma globulin fraction (%) was determined by serum protein electrophoresis, and gamma globulin level (mg/dL) was calculated by multiplying the total protein level (mg/ dL) by the gamma globulin fraction (%). The association between gamma globulin levels and clinicopathological variables, including oncological outcomes, was statistically evaluated.
RESULTS: During a median follow-up period of 39 months, 99 (36.1%) patients experienced at least one tumor recurrence and 16 (5.8%) patients developed muscle invasive disease. The median (interquartile range) gamma globulin level was 1.2 (1.0-1.3) mg/dL. A significant difference in recurrence-free survival was found between patients with gamma globulin levels of !1.4 and <1.4 mg/dL (p < 0.01), but not in progression-free survival (p [ 0.17) between the two groups. Multivariate analysis revealed that gamma globulin level of !1.4 mg/dL is significantly associated with tumor recurrence (hazard ratio [ 1.83, p < 0.01).
CONCLUSIONS: A high gamma globulin level was significantly associated with tumor recurrence. Our results suggest that B cell immunity may be involved in tumor recurrence in NMIBC patients.
INTRODUCTION AND OBJECTIVES: For patients with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacille
Calmette-Guerin (BCG), multi-agent intravesical trials have been limited. The goal of this study was to investigate the safety of intravesical chemotherapy consisting of sequential cabazitaxel, gemcitabine, and cisplatin (CGC) in the salvage setting. Funding support for the trial was provided by Sanofi Genzyme.
METHODS: This was a dose-escalation, drug-escalation trial enrolling patients with BCG refractory or recurrent high-risk NMIBC who refused or were ineligible for radical cystectomy. All patients underwent a pre-treatment transurethral resection of bladder tumor (TURBT) and a 6-week regimen of intravesical chemotherapy, with each drug instilled weekly except for cisplatin, which was given every other week. Complete response was defined as no evidence of cancer on post-induction TURBT and negative urine cytology; these patients proceeded with monthly and bimonthly maintenance therapy in the first and second years, respectively, for a total of 24 months. Toxicity was categorized according to Common Terminology for Adverse Events v4.
RESULTS: Eighteen patients were enrolled, of whom four were female. Mean age was 71 years, median follow-up was 13 months, and mean number of previous rounds of intravesical therapies prior to enrollment was 3.7. All patients had previously received at least two prior induction cycles of BCG, and 17/18 patients (94%) were BCG refractory. Nine patients (50%) previously received intravesical chemotherapy after BCG (AE IFN), seven (39%) of whom were previously treated in a Phase I clinical trial setting. All patients had high grade disease at enrollment, with 9/18 (50%) patients with T1 and 12/18 (67%) patients with CIS. There were no dose-limiting toxicities. Initial complete response rate was 94%. At last follow up, four patients (22%) recurred at median time of 9.5 months, though two patients recurred in the prostatic urethra (both of whom had high grade disease in the prostatic urethra immediately prior to enrollment). Three patients (17%) underwent cystectomy at median time of 12 months. Fourteen patients (78%) remained disease-free at last follow up.
CONCLUSIONS: Combination intravesical cabazitaxel, gemcitabine, and cisplatin appears to be a well-tolerated, promising salvage chemotherapy regimen for the treatment of BCG unresponsive NMIBC.
Source of Funding: Sanofi Genzyme

MP43-15 THE USEFULNESS OF NON-INVASIVE TESTS AS A REPLACEMENT FOR CYSTOSCOPY IN THE FOLLOW-UP OF NON-INVASIVE BLADDER CANCER
INTRODUCTION AND OBJECTIVES: Bladder cancer has a high recurrence rate compared to other solid organ cancers which is less life-threatening. However because of high recurrence rate followup examination as cystoscopy is very frequent. With the development of optical technology, cystoscopy became flexible with smaller diameter these days and patient's discomfort has reduced. However, cystoscopy still remains as an unwanted examination not only for patients but also for urologists with several reasons. As gold standard for bladder cancer follow-up still remain as cystoscopy we aimed to investigate the possibility of follow-up with non-invasive studies only.
METHODS: A retrospective study was done for transurethral resection of bladder tumor performed by a single surgeon between May 2005 and May 2018. All decision of TUR-BT was made after cystoscopic evaluation at the clinic. Only cases from 2nd TUR-BT and cases with pre-operative bladder MRI within one month were included for the analysis. A multi-parametric bladder MRI was performed using a 3.0 Tesla MRI machines. Bladder MRI reports, urine cytology and surgical pathology reports were analyzed for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for bladder lesion.
RESULTS: From total of 2258 cases, 1532 cases of initial TUR-BT and 481 cases without pre-operative bladder MRI within 1 month prior to TUR-BT were excluded. Finally total of 245 cases of 195 patients were analyzed. During median follow up of 13.6 months (6.7e28.6) after each TUR-BT, 1235 cases of cystoscopy was performed for follow-up. However, with preoperative urine cytology and bladder MRI together bladder cancer detection rate showed to be sensitivity of 95.1%, specificity of 42.9%, positive predictive value (PPV) of 88.9% and negative predictive value (NPV) of 64.3 %. Among nine of false negative cases, three were missed by radiologist, four had gross hematuria and one had appropriate bladder filling before MRI. Only one case was missed with every other signs and symptoms. However none of false negative cases showed rapid extensive progression to radical or partial cystectomy.
CONCLUSIONS: Within the era of developing imaging technique as MRI, efforts to avoid patient's discomfort should be done. Noninvasive test results as urine cytology and MRI can reduce performed number of cystoscopy and succeed in bladder cancer follow-up without unexpected progressions. Also detection for kidney or prostate cancer and lymph node evaluation can be done periodically with the MRI. However, follow-up schedule and investigation for larger cohort is needed.
